| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/07/2002 | EP1227800A1 Osmotic controlled release drug delivery device |
| 08/07/2002 | EP1227797A2 Solid dispersion pharmaceutical formulations |
| 08/07/2002 | EP1227795A2 Lipid complex of alkycyclines |
| 08/07/2002 | EP1227734A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 08/07/2002 | EP1227721A1 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 08/07/2002 | EP1156789A4 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 08/07/2002 | EP1039912B1 Angiostatic agents and compositions for treating glc1a glaucoma |
| 08/07/2002 | EP0981330B1 Topical compositions |
| 08/07/2002 | EP0912097B1 Antimicrobial peroxidase compositions |
| 08/07/2002 | EP0831856B1 Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device |
| 08/07/2002 | EP0809517B1 Anti-transforming growth factor-beta gene therapy |
| 08/07/2002 | EP0701434B1 Preparations containing silicon dioxide to improve the taste thereof |
| 08/07/2002 | EP0689434B1 Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof |
| 08/07/2002 | CN1362968A Novel peptides |
| 08/07/2002 | CN1362953A Pyrazole compositions useful as inhibitors of ERK |
| 08/07/2002 | CN1362947A N-cyanomethylamides as protease inhibitors |
| 08/07/2002 | CN1362880A Immunomodulating polymers |
| 08/07/2002 | CN1088585C Compound active at novel site on receptor-operated calcium channels use full for treatment of neurological disorders and diseases |
| 08/06/2002 | US6429313 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 08/06/2002 | US6429303 Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
| 08/06/2002 | US6429224 Use of taurolidine to treat tumors |
| 08/06/2002 | US6429217 Pharmacological drug combination in vagal-induced asystole |
| 08/06/2002 | US6429209 5-ht3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome |
| 08/06/2002 | US6429206 Using agonist of nicotinergic acetylcholine receptors |
| 08/06/2002 | US6429203 Farnesyl-protein transferase inhibitors |
| 08/06/2002 | US6429198 Compositions for increasing athletic performance in mammals |
| 08/06/2002 | US6429197 Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 08/06/2002 | US6429188 Vasoactive intestinal peptide and peptide activating hypofissiary adenylate cyclase; inhibiting production of tumor necrosis factor and interleukin 6; amino acid seq id no:1, 2 and 3 |
| 08/06/2002 | US6429012 Cell population containing non-fetal hemangioblasts and method for producing same |
| 08/06/2002 | US6428977 Transforming growth factor-beta (tgf-beta); nucleic acid; polypeptide promotes the formation of ventral mesoderm in xenopus animal pole explants; use promoting osteogenesis for example |
| 08/06/2002 | US6428950 Culturing glial cells which express apolipoprotein e at known level, contacting cells with compound to be tested, comparing apolipoprotein e expression of glial cells in contact with compound with apolipoprotein e expression in control culture |
| 08/06/2002 | US6428818 Dietary or nutritional supplements and therapeutics for prevention and treatment of cancer; epicatechin and epigallocatechin gallate at 10:1 ratio; gallic acid free |
| 08/06/2002 | US6428814 Stabilizers prevent aggregation of nanoparticles and increase bioadhesion to substrates such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, and/or plant tissue |
| 08/06/2002 | US6428809 Metering and packaging of controlled release medication |
| 08/06/2002 | US6428800 Mixture of bioactive glass and topical antibiotic |
| 08/06/2002 | US6428791 Plant or herb extracts and l-arginine; enhances blood circulation to mucosal areas and/or increases nitrous oxide levels; nonirritating |
| 08/06/2002 | US6428788 Preferential drug delivery to tumors having interleukin receptors; side effect reduction |
| 08/06/2002 | US6428785 Local administration of therapeutically effective concentration of collagenase for therapy of prostate cancer in mammal |
| 08/06/2002 | US6428782 Non-myeloablative tolerogenic treatment |
| 08/06/2002 | US6428780 Modified amino acid |
| 08/06/2002 | US6428500 Adhesion prevention and an endoscopic insufflation system therefor |
| 08/02/2002 | CA2369789A1 Combination treatment for depression |
| 08/01/2002 | WO2002059612A2 Animal model and cell-line expressing modified chlorine channel |
| 08/01/2002 | WO2002059609A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | WO2002059558A2 Means and methods for treatment evaluation |
| 08/01/2002 | WO2002059373A2 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 08/01/2002 | WO2002059363A2 Method for detecting of prions in a sample |
| 08/01/2002 | WO2002059361A1 Use of the slug gene or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells |
| 08/01/2002 | WO2002059356A2 Method for screening compounds for activity in treating an osteoclast related bone disease |
| 08/01/2002 | WO2002059327A2 Sulfatases and methods of use thereof |
| 08/01/2002 | WO2002059326A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 08/01/2002 | WO2002059323A2 Aminoacyl trna synthetases |
| 08/01/2002 | WO2002059312A2 Cell adhesion proteins |
| 08/01/2002 | WO2002059310A2 Polynucleotides encoding cellular transporters and methods of use thereof |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059293A2 Process and compositions for peptide, protein and peptidomimetic synthesis |
| 08/01/2002 | WO2002059286A2 Adenylate cyclases |
| 08/01/2002 | WO2002059283A2 Nucleic acid modification enzymes |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059154A2 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | WO2002059150A2 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 08/01/2002 | WO2002059135A1 Compositions containing a ruthenium(iii) complex and a heterocycle |
| 08/01/2002 | WO2002059117A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059108A1 Melanocortin receptor agonists |
| 08/01/2002 | WO2002059095A1 Melanocortin receptor agonists |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002058793A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
| 08/01/2002 | WO2002058792A2 Rehydration composition |
| 08/01/2002 | WO2002058735A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | WO2002058734A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 08/01/2002 | WO2002058733A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058732A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058731A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058717A2 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 08/01/2002 | WO2002058715A1 Prevention of diabetes by administration of gnrh antagonists |
| 08/01/2002 | WO2002058705A2 Degradation-resistant glucocorticosteroid formulations |
| 08/01/2002 | WO2002058700A1 Methods of administering epothilone analogs for the treatment of cancer |
| 08/01/2002 | WO2002058696A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | WO2002058694A2 Method of treating hematologic tumors and cancers using beta lapachone |
| 08/01/2002 | WO2002058692A2 Halogenated composition, method for preparing same and uses thereof |
| 08/01/2002 | WO2002058688A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | WO2002058685A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058684A2 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 08/01/2002 | WO2002058683A2 Carotenoids as anti-hypertension agents |
| 08/01/2002 | WO2002058681A2 Use of rhein for preparing a medicine for treating a high level of il-1 |
| 08/01/2002 | WO2002058676A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
| 08/01/2002 | WO2002058640A1 Topical therapeutic skin care system |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058623A2 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 08/01/2002 | WO2002058620A2 Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant |
| 08/01/2002 | WO2002058546A2 Methods for screening for substances which inhibit fp prostanoid receptor |
| 08/01/2002 | WO2002058535A2 Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
| 08/01/2002 | WO2002058532A2 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof |